These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36527025)

  • 1. Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design.
    Benza RL; Franco V; Aras MA; Spikes L; Grinnan D; Satler C
    Respir Res; 2022 Dec; 23(1):355. PubMed ID: 36527025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects.
    Eldon MA; Parsley EL; Maurer M; Tarara TE; Okikawa J; Weers JG
    J Aerosol Med Pulm Drug Deliv; 2021 Aug; 34(4):251-261. PubMed ID: 33325799
    [No Abstract]   [Full Text] [Related]  

  • 3. Right ventricular energetic biomarkers from 4D Flow CMR are associated with exertional capacity in pulmonary arterial hypertension.
    Zhao X; Leng S; Tan RS; Chai P; Yeo TJ; Bryant JA; Teo LLS; Fortier MV; Ruan W; Low TT; Ong CC; Zhang S; van der Geest RJ; Allen JC; Hughes M; Garg P; Tan TH; Yip JW; Tan JL; Zhong L
    J Cardiovasc Magn Reson; 2022 Dec; 24(1):61. PubMed ID: 36451198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization.
    Correale M; Monaco I; Ferraretti A; Tricarico L; Sicuranza M; Gallotta AM; Formica ES; Acanfora G; Di Biase M; Brunetti ND
    Int J Cardiol Heart Vasc; 2020 Jun; 28():100513. PubMed ID: 32346602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ECG in the clinical and prognostic evaluation of patients with pulmonary arterial hypertension: an underestimated value.
    Michalski TA; Pszczola J; Lisowska A; Knapp M; Sobkowicz B; Kaminski K; Ptaszynska-Kopczynska K
    Ther Adv Respir Dis; 2022; 16():17534666221087846. PubMed ID: 35442108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of exercise capacity in female systemic lupus erythematosus associated pulmonary arterial hypertension patients.
    Pudasaini B; Yang GL; Yang C; Guo J; Yuan P; Wen-Lan Y; Zhang R; Wang L; Zhao QH; Gong SG; Jiang R; Chen TX; Wei X; Liu JM
    BMC Cardiovasc Disord; 2018 Mar; 18(1):56. PubMed ID: 29566672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP).
    Stollfuss B; Richter M; Drömann D; Klose H; Schwaiblmair M; Gruenig E; Ewert R; Kirchner MC; Kleinjung F; Irrgang V; Mueller C
    J Med Internet Res; 2021 Oct; 23(10):e25163. PubMed ID: 34623313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
    BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
    Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
    N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Clinical Outcomes and Simultaneous Digital Tracking of Daily Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Protocol for the Observational VENTASTEP Study.
    Mueller C; Stollfuss B; Roitenberg A; Harder J; Richter MJ
    JMIR Res Protoc; 2019 Apr; 8(4):e12144. PubMed ID: 30985279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial.
    Chang HJ; Song S; Chang SA; Kim HK; Jung HO; Choi JH; Lee JS; Kim KH; Jeong JO; Lee JH; Kim DK
    Clin Ther; 2019 Aug; 41(8):1499-1507. PubMed ID: 31202506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.
    Jing ZC; Yu ZX; Shen JY; Wu BX; Xu KF; Zhu XY; Pan L; Zhang ZL; Liu XQ; Zhang YS; Jiang X; Galiè N;
    Am J Respir Crit Care Med; 2011 Jun; 183(12):1723-9. PubMed ID: 21471085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
    Barnes H; Brown Z; Burns A; Williams T
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.
    Hoenicka M; Golovchenko S; Englert L; Spaeth M; Shoshiashvili L; Großer C; Hofmann HS; Ried M
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):287-295. PubMed ID: 30826900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.
    Spikes LA; Bajwa AA; Burger CD; Desai SV; Eggert MS; El-Kersh KA; Fisher MR; Johri S; Joly JM; Mehta J; Palevsky HI; Ramani GV; Restrepo-Jaramillo R; Sahay S; Shah TG; Deng C; Miceli M; Smith P; Shapiro SM
    Pulm Circ; 2022 Apr; 12(2):e12063. PubMed ID: 35514770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.